| 氏名 |
白杉 由香理 |
| フリガナ(ローマ字) |
シラスギ ユカリ(Yukari Shirasugi) |
| 職名 |
教授 |
| 学位 |
博士(医学) |
| 担当授業科目 |
薬物治療学,症侯論,実務実習事前学習,チーム医療論,医療薬学チュートリアル演習,早期臨床体験実習,後期臨床体験実習,病院実務実習,薬学総合プレ研究,卒業研究,総合演習など |
| 専門分野 |
血液内科,腫瘍内科,内科学 |
| 現在の研究テーマ |
免疫性血小板減少症 |
| 研究内容キーワード |
免疫性血小板減少症,血液難病患者におけるHRQoL,がん薬物療法における多職種連携 |
| 主な著書・学術論文 |
【主な著書】 |
| 内科レジデント実践マニュアル 第12版 三井記念病院内科編集.(分担執筆 白杉由香理)文光堂.2025年 |
| 看護学テキスト NICE病態・治療論[6] 血液・造血器疾患改定第2版 小川吉明,横田弘子編集.(分担執筆 白杉由香理)南江堂.2025年 |
| インフォームドコンセントのための図説シリーズ 抗悪性腫瘍薬分子標的治療薬 改訂版 西條長宏編.(分担執筆 白杉由香理)医薬ジャーナル社.2015年 |
| 【主な総説和文】 |
| 時系列でみる血球異常の治療 15血小板減少症.月間薬事.株式会社じほう.2023;65:96-100. |
| 出血性疾患と血栓性疾患 特発性血小板減少性紫斑病(成人)の治療.Medical Practice. 文光堂.2018; 35:1095-1099. |
| 副腎皮質ステロイド 副腎皮質ステロイドのコンセンサスとコントラバーシー インフュージョンリアクション 薬局. 南山堂.2015; 66:102-109. |
| 【論文】 |
| Miyazawa K, Shirasugi Y, Imai E, Tanaka J, Toda J, Narukawa K, Mitsui Y, Takahashi T. Pericardial Calcification Following Acute Myopericarditis After Initial CHOP Treatment for Mantle Cell Lymphoma: A Case Report.Cureus. 2025; 17:e88634. doi:10.7759/cureus.88634. |
| Seki H, Narukawa K, Mitsui Y, Shirasugi Y, Morita S, Takahashi T. Calcium Polystyrene Sulfonate Crystal-related Airway Obstruction. Intern Med. 2024; 63:2699-2701 |
| Ishiyama K, Yonemura Y, Kawaguchi T, Hosokawa K, Sugimori C, Ueda Y, Takamori H, Obara N, Noji H, Shirasugi Y, Ando K, Shichishima T, Ninomiya H, Chiba S, Nishimura JI, Kanakura Y, Nakao S. A longitudinal analysis of paroxysmal nocturnal haemoglobinuria-type cells in patients with bone marrow failure: Results of a prospective multi-centre study in Japan. Br J Haematol. 2023; 203:468-476. |
| Fujisawa H, Mitsui Y, Narukawa K, Shirasugi Y, Komaki S, Hao A, Matsumoto H, Takahashi T.Methotrexate-induced Subacute Encephalopathy That Showed No Abnormalities on Magnetic Resonance Imaging Soon after Symptom Appearance. Intern Med. 2023; 62:2249-2252. |
| Hosokawa K, Ishiyama K, Ikemoto T, Sugimori C, Noji H, Shichishima T, Obara N, Chiba S, Ninomiya H, Nguyen MAT, Shirasugi Y, Nakamura Y, Ando K, Ueda Y, Yonemura Y, Kawaguchi T, Nishimura JI, Kanakura Y, Nakao S. The clinical significance of PNH-phenotype cells accounting for < 0.01% of total granulocytes detected by the Clinical and Laboratory Standards Institute methods in patients with bone marrow failure. Ann Hematol. 2021; 100:1975-1982. |
| Munakata W, Shirasugi Y, Tobinai K, Onizuka M, Makita S, Suzuki R, Maruyama D, Kawai H, Izutsu K, Nakanishi T, Shiba S, Hojo S, Ando K. Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma. Cancer Sci. 2021; 112:1123-1131. |
| Munakata W, Ando K, Hatake K, Fukuhara N, Kinoshita T, Fukuhara S, Shirasugi Y, Yokoyama M, Ichikawa S, Ohmachi K, Gion N, Aoi A, Tobinai K. Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan. Cancer Sci. 2019; 110:1686-1694. |
| Kanakura Y, Shirasugi Y, Yamaguchi H, Koike M, Chou T, Okamoto S, Achenbach H, Wu J, Nakaseko C. A phase 3b, multicenter, open-label extension study of the long-term safety of anagrelide in Japanese adults with essential thrombocythemia. Int J Hematol. 2018; 108:491-498. |
| Maruyama D, Hatake K, Kinoshita T, Fukuhara N, Choi I, Taniwaki M, Ando K, Terui Y, Higuchi Y, Onishi Y, Abe Y, Kobayashi T, Shirasugi Y, Tobinai K. Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. Cancer Sci. 2017; 108:1007-1012. |
| Miyakawa Y, Katsutani S, Yano T, Nomura S, Nishiwaki K, Tomiyama Y, Higashihara M, Shirasugi Y, Nishikawa M, Ozaki K, Abe T, Kikuchi K, Kanakura Y, Fujimura K, Ikeda Y, Okamoto S. Efficacy and safety of rituximab in Japanese patients with relapsed chronic immune thrombocytopenia refractory to conventional therapy. Int J Hematol. 2015; 102:654-661. |
| Ogawa Y, Ogura M, Suzuki T, Ando K, Uchida T, Shirasugi Y, Tobinai K, Lee JH, Kase M, Katsura K, Hotta T. A phase I/II study of ofatumumab (GSK1841157) in Japanese and Korean patients with relapsed or refractory B-cell chronic lymphocytic leukemia. Int J Hematol. 2013; 98:164-70. |
| Shirasugi Y, Ando K, Miyazaki K, Tomiyama Y, Iwato K, Okamoto S, Kurokawa M, Kirito K, Hashino S, Ninomiya H, Mori S, Yonemura Y, Usuki K, Wei H, Lizambri R. An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP). Int J Hematol. 2012; 95:652-9. |
| Shirasugi Y, Ando K, Miyazaki K, Tomiyama Y, Okamoto S, Kurokawa M, Kirito K, Yonemura Y, Mori S, Usuki K, Iwato K, Hashino S, Wei H, Lizambri R. Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial. Int J Hematol. 2011; 94:71-80. |
| Shirasugi Y, Ando K, Hashino S, Nagasawa T, Kurata Y, Kishimoto Y, Iwato K, Ohtsu T, Berger DP. A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura. Int J Hematol. 2009; 90:157-65. |